巨囊性病液状蛋白-15在肺癌中的表达研究

摘要
图/表
参考文献(21)
相关文章 (15)

全文: PDF (873 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要

目的探讨巨囊性病液状蛋白-15 （GCDFP-15）在肺癌中的表达情况及作用。方法利用癌症基因组图谱（TCGA）数据库分析肺癌组织及癌旁组织中GCDFP-15 的表达差异；不同临床分期肺癌患者的GCDFP-15 的表达差异及对GCDFP-15 高/低表达组的肺癌患者进行生存期比较。采用酶联免疫吸附试验（ELISA）检测肺癌患者及对照组血浆中的GCDFP-15 水平；采用定量逆转录PCR（RT-qPCR）和Western blot 分别检测4 株肺癌细胞系与1株支气管上皮细胞系中的GCDFP-15 mRNA 和蛋白表达量；ELISA 实验检测以上5 株细胞系培养液上清中的GCDFP-15 浓度，综合分析GCDFP-15 在肺癌中的表达情况。结果 TCGA 数据库显示在肺腺癌和鳞癌中的GCDFP-15 的表达、不同临床分期肺癌患者的GCDFP-15 表达、低表达组与高表达组的中位生存期比较，差异无统计学意义（P>0.05）。肺癌组患者血浆中的GCDFP-15 浓度高于正常对照组，差异有统计学意义（P＜0.05）。4 个肺癌细胞株的GCDFP-15 mRNA 均高于支气管上皮细胞，差异有统计学意义（P＜0.05）。 Western Blot 结果显示这5 株细胞均未检测到GCDFP-15 蛋白，在细胞培养液上清中检测到GCDFP-15，且4 株肺癌细胞系中，A549 和H620培养基上清中的GCDFP-15 表达均高于16HBE，差异有统计学意义（P＜0.05）。结论肺癌患者血浆中的GCDFP-15 蛋白高于正常对照组，4 株肺癌细胞系的GCDFP-15 mRNA 均高于支气管上皮细胞系，2 株肺癌细胞系培养液上清中的GCDFP-15 蛋白高于支气管上皮细胞系，结合TCGA 数据库分析的结果，推测GCDFP-15 可能是肺癌的一个肿瘤标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：肺癌, 巨囊性病液体蛋白-15, 泌乳素诱导蛋白, 酶联免疫吸附试验, 乳腺癌

Abstract：

Objective To investigate the expression and role of gross cystic disease fluid protein-15 (GCDFP-15) in lung cancer. Methods The cancer genome atlas (TCGA) database was used to analyze the differences in the expression of GCDFP-15 in lung cancer tissues and adjacent tissues; the differences in the expression of GCDFP-15 in lung cancer patients with different clinical stages and then to compare the survival time of lung cancer patients in the GCDFP-15 high/low expression group. GCDFP-15 levels in plasma of lung cancer patients and control group were detected by enzyme-linked immunosorbent assay (ELISA). Quantitative reverse transcription PCR (RT-qPCR) and Western blot were used to detect the expression of GCDFP-15 mRNA and protein in 4 lung cancer cell lines and 1 bronchial epithelial cell line, respectively. The concentration of GCDFP-15 in the supernatant of culture medium of the above 5 cell lines was detected by ELISA, and the expression of GCDFP-15 in lung cancer was comprehensively analyzed.Results TCGA database showed that there were no statistically significant differences in the expression of GCDFP-15 in lung adenocarcinoma and squamous cell carcinoma, the expression of GCDFP-15 in lung cancer patients with different clinical stages, and the median survival between low expression group and high expression group (P>0.05). The plasma concentration of GCDFP-15 in lung cancer group was higher than that in normal control group, and the difference was statistically significant (P<0.05). The GCDFP-15 mRNA of 4 lung cancer cell lines was higher than that of bronchial epithelial cells, and the difference was statistically significant (P<0.05). Western Blot results showed that GCDFP-15 protein was not detected in all the 5 cell lines, and GCDFP-15 was detected in the supernatant of cell culture medium, and the expression of GCDFP-15 in the supernatant of A549 and H620 medium was higher than that of 16HBE in all the 4 lung cancer cell lines, the difference was statistically significant (P＜0.05). Conclusion GCDFP-15 in plasma of lung cancer patients was higher than that of normal control group, GCDFP-15 mRNA in 4 lung cancer cell lines was significantly higher than that of bronchial epithelial cell lines, GCDFP-15 in supernatant of culture medium of 2 lung cancer cell lines was higher than that of bronchial epithelial cell lines. Combined with the results of TCGA database analysis, it is speculated that GCDFP-15 may be a tumor marker of lung cancer.

Key words： Lung cancer Gross cystic disease fluid protein-15 Prolactin inducible protein Enzyme-linked immunosorbent assay Breast cancer

基金资助:福建医科大学启航基金项目（2017XQ1105）；
福建省中青年教师教育科研项目（JT180195）；
福建省泉州市科技计划项目（2018N010S）

引用本文:

周爽;苏小珊;林国福;刘怡飞;高宏志. 巨囊性病液状蛋白-15在肺癌中的表达研究[J]. 中国当代医药, 2022, 29(12): 9-14.
ZHOU Shuang SU Xiaoshan LIN Guofu LIU Yifei GAO Hongzhi▲. Study on the expression of gross cystic disease fluid protein- 15 in lung cancer. 中国当代医药, 2022, 29(12): 9-14.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I12/9

[3]	Urbaniak A，Jablonska K，Podhorska-Okolow M，et al.Prolactin-induced protein （PIP）-characterization and role in breast cancer progression[J].Am J Cancer Res，2018，8（11）：2150-2164.
[4]	Jablonska K，Grzegrzolka J，Podhorska-Okolow M，et al.Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients[J].Am J Cancer Res，2016，6（5）：878-893.
[5]	Hassan MI，Waheed A，Yadav S，et al.Prolactin inducible protein in cancer，fertility and immunoregulation：structure，function and its clinical implications[J].Cell Mol Life Sci，2009，66（3）：447-459.
[6]	Ihedioha O，Blanchard AA，Balhara J，et al.The human breast cancer-associated protein，the prolactin-inducible protein（PIP），regulates intracellular signaling events and cytokine production by macrophages[J].Immunol Res，2018，66（2）：245-254.
[7]	Edechi CA，Nasr MR，Karim A，et al.The prolactin inducible protein/gross cystic disease fluid protein-15 deficient mice develop anomalies in lymphoid organs[J].Immunobiology，2019，224（6）：811-816.
[8]	López-Otín C，Diamandis EP.Breast and prostate cancer：an analysis of common epidemiological，genetic，and biochemical features[J].Endocr Rev，1998，19（4）：365-396.
[9]	Takeda Y，Tsuta K，Shibuki Y，et al.Analysis of expression patterns of breast cancer-specific markers （mammaglobin and gross cystic disease fluid protein 15） in lung and pleural tumors[J].Arch Pathol Lab Med，2008，132（2）：239-243.
[10]	Ni YB，Tsang JYS，Shao MM，et al.GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer[J].Breast Cancer Res Treat，2018，169（1）：25-32.
[11]	Borhan WM，Cimino-Mathews AM，Montgomery EA，et al.Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder[J].Am J Surg Pathol，2017，41（11）：1570-1575.
[12]	Edechi CA，Ikeogu N，Uzonna JE，et al.Regulation of Immunity in Breast Cancer[J].Cancers （Basel），2019，11（8）：1080.
[13]	Park JH，Kim JH.Pathologic differential diagnosis of metastatic carcinoma in the liver[J].Clin Mol Hepatol，2019，25（1）：12-20.
[16]	刘君.重症肺炎患者血泌乳素水平变化及其临床意义[D].石家庄：河北医科大学，2016.
[19]	Osawa M，Horiuchi H，Tian W，et al.Divergent evolution of the prolactin-inducible protein gene and related genes in the mouse genome[J].Gene，2004，325：179-186.
[14]	Lagendijk JH，Mullink H，van Diest PJ，et al.Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin.Comparison between a statistical and an intuitive approach[J].J Clin Pathol，1999，52（4）：283-290.
[15]	Sriram R，Lo V，Pryce B，et al.Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptorpositive molecular apocrine-like tumors with reduced Notch1 activity[J].Breast Cancer Res，2015，17（1）：7.
[17]	Sharif R，Bak-Nielsen S，Hjortdal J，et al.Pathogenesis of Keratoconus：The intriguing therapeutic potential of Prolactin-inducible protein[J].Prog Retin Eye Res，2018，67：150-167.
[18]	Priyadarsini S，Hjortdal J，Sarker-Nag A，et al.Gross cystic disease fluid protein-15/prolactin-inducible protein as a biomarker for keratoconus disease[J].PLoS One，2014，9（11）：e113310.
[20]	Hassan MI，Waheed A，Yadav S，et al.Prolactin inducible protein in cancer，fertility and immunoregulation：structure，function and its clinical implications[J].Cell Mol Life Sci，2009，66（3）：447-459.
[21]	Striebel JM，Dacic S，Yousem SA.Gross cystic disease fluid protein-（GCDFP-15）：expression in primary lung adenocarcinoma[J].Am J Surg Pathol，2008，32（3）：426-432.
[1]	Herbst RS，Morgensztern D，Boshoff C.The biology and management of non-small cell lung cancer[J].Nature，2018，553（7689）：446-454.
[2]	Ihedioha OC，Shiu RP，Uzonna JE，et al.Prolactin-Inducible Protein：From Breast Cancer Biomarker to Immune Modulator-Novel Insights from Knockout Mice[J].DNA Cell Biol，2016，35（10）：537-541.